Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Kyowa Kirin Co., Ltd.    4151   JP3256000005

KYOWA KIRIN CO., LTD.

(4151)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
01/18/2021 01/19/2021 01/20/2021 01/21/2021 01/22/2021 Date
2820 2856 2841 2826 2778 Last
477800 625100 560300 502400 457800 Volume
+0.07% +1.28% -0.53% -0.53% -1.70% Change
Financials
Sales 2020 321 B 3 090 M 3 090 M
Net income 2020 48 127 M 464 M 464 M
Net cash position 2020 192 B 1 849 M 1 849 M
P/E ratio 2020 31,3x
Yield 2020 1,58%
Sales 2021 348 B 3 355 M 3 355 M
Net income 2021 57 027 M 549 M 549 M
Net cash position 2021 224 B 2 161 M 2 161 M
P/E ratio 2021 26,2x
Yield 2021 1,67%
Capitalization 1 492 B 14 378 M 14 378 M
EV / Sales 2020 4,05x
EV / Sales 2021 3,64x
Nbr of Employees 5 267
Free-Float 45,8%
More Financials
Company
Kyowa Kirin Co., Ltd. (formerly Kyowa Hakko Kirin Co., Ltd.) specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows: - sales of pharmaceutical products (94.1%): prescription products for anemia, cancers, immune and nephrology diseases treatment; - sales of licenses (5.9%). At the end of 2019, the group had 3... 
More about the company
Notations Surperformance© of Kyowa Kirin Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about KYOWA KIRIN CO., LTD.
01/05MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Cl..
AQ
2020KYOWA KIRIN CO., LTD. : Ex-dividend day for final dividend
FA
2020KYOWA KIRIN : Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and di..
AQ
2020PRESS RELEASE : Helsinn and Kyowa Kirin Asia -2-
DJ
2020PRESS RELEASE : Helsinn and Kyowa Kirin Asia Pacific sign exclusive license and ..
DJ
2020MEI Pharma Reports First Quarter Fiscal Year 2021 Results and Operational Hig..
AQ
2020KYOWA KIRIN CO., LTD. : quaterly earnings release
2020Kyowa Kirin and MEI Pharma Announce First Patient Dosed in Japanese Pivotal P..
AQ
2020MEI Pharma Reports Fiscal Year 2020 Results and Operational Highlights
AQ
2020Japan's Kirin, hit by virus, says helped by expansion beyond beer
RE
2020KYOWA KIRIN : Appendix to the Consolidated Financial Summary (IFRS) Fiscal 2020 ..
PU
2020KYOWA KIRIN : Consolidated Financial Summary (IFRS) Fiscal 2020 Interim
PU
2020KYOWA KIRIN CO., LTD. : Press Release
CO
2020KYOWA KIRIN CO., LTD. : Half-year results
CO
2020Japan shares hit 5-week high on vaccine, economic growth hopes
RE
More news
News in other languages on KYOWA KIRIN CO., LTD.
2020KYOWA KIRIN CO., LTD. : Veröffentlichung des Quartalsergebnisses
2020KYOWA KIRIN CO., LTD. : publication des résultats trimestriels
2020Borsa Tokyo a massimi di cinque settimane su speranze vaccino, ripresa econom..
2020KYOWA KIRIN CO., LTD. : publication des résultats annuels
2020KYOWA KIRIN CO., LTD. : Veröffentlichung des Jahresergebnisses
More news
Chart KYOWA KIRIN CO., LTD.
Duration : Period :
Kyowa Kirin Co., Ltd. Technical Analysis Chart | 4151 | JP3256000005 | MarketScreener
Technical analysis trends KYOWA KIRIN CO., LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Average target price 3 425,00 JPY
Last Close Price 2 778,00 JPY
Spread / Highest target 51,2%
Spread / Average Target 23,3%
Spread / Lowest Target -2,81%
EPS Revisions
Managers and Directors
NameTitle
Masashi Miyamoto President, CEO & Representative Director
Nobuo Hanai Chairman
Motohiko Kawaguchi Executive Officer, Manager-Accounting & Finance
Mitsuo Satoh Executive Officer, GM-Research & Development
Toshifumi Mikayama Director & Senior Managing Executive Officer
Sector and Competitors
1st jan.Capitalization (M$)
KYOWA KIRIN CO., LTD.-1.28%14 661
MERCK KGAA0.64%74 584
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD11.98%27 823
BETTA PHARMACEUTICALS CO., LTD.33.28%8 595
YUHAN CORPORATION-3.60%4 335
RECIPHARM AB (PUBL)3.92%2 773